XOMA Co. (NASDAQ:XOMA) CIO Bradley Sitko Buys 4,134 Shares

XOMA Co. (NASDAQ:XOMA - Get Free Report) CIO Bradley Sitko bought 4,134 shares of the stock in a transaction that occurred on Friday, March 21st. The shares were purchased at an average price of $23.89 per share, for a total transaction of $98,761.26. Following the completion of the acquisition, the executive now owns 10,484 shares of the company's stock, valued at $250,462.76. The trade was a 65.10 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Bradley Sitko also recently made the following trade(s):

• On Wednesday, January 8th, Bradley Sitko acquired 313 shares of XOMA stock. The stock was purchased at an average cost of $25.60 per share, with a total value of $8,012.80.
• On Tuesday, December 31st, Bradley Sitko bought 300 shares of XOMA stock. The stock was purchased at an average price of $25.90 per share, with a total value of $7,770.00.

XOMA Stock Performance

Shares of XOMA stock traded down $0.64 on Friday, hitting $20.33. The stock had a trading volume of 11,774 shares, compared to its average volume of 27,230. The stock has a market cap of $243.53 million, a price-to-earnings ratio of -5.84 and a beta of 1.00. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA Co. has a twelve month low of $19.92 and a twelve month high of $35.00. The business's 50 day moving average is $23.76 and its two-hundred day moving average is $26.90.

Remove Ads

XOMA (NASDAQ:XOMA - Get Free Report) last issued its quarterly earnings data on Monday, March 17th. The biotechnology company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The firm had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.75 million. Analysts forecast that XOMA Co. will post -1.41 EPS for the current year.

Institutional Investors Weigh In On XOMA

A number of large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its position in shares of XOMA by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company's stock valued at $4,840,000 after acquiring an additional 1,138 shares during the period. Barclays PLC lifted its position in XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company's stock worth $298,000 after purchasing an additional 8,447 shares during the period. BNP Paribas Financial Markets grew its stake in XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company's stock worth $43,000 after buying an additional 795 shares in the last quarter. State Street Corp increased its holdings in XOMA by 1.2% in the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company's stock valued at $3,783,000 after buying an additional 1,754 shares during the period. Finally, New York State Common Retirement Fund raised its position in shares of XOMA by 51.2% in the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock valued at $62,000 after buying an additional 800 shares in the last quarter. Institutional investors and hedge funds own 95.92% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. StockNews.com raised XOMA from a "sell" rating to a "hold" rating in a research report on Friday, March 21st. HC Wainwright reaffirmed a "buy" rating and set a $104.00 price objective on shares of XOMA in a research report on Friday.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.